HOME >> BIOLOGY >> NEWS
Nano design adjustment may help find, clear some water contaminants

e off-centered anion-interactions occurring through a charge-transfer interaction," Berryman said. "We looked at solid-state structures and the geometry of the interaction involved in a simple system. In these initial studies we noted significant color changes due to this off-center binding geometry found in the crystal structures."

Co-principal investigator Benjamin P. Hay, a chemist at the Pacific Northwest National Laboratory in Richland, Wash., where Berryman studied last fall as part of UO's National Science Foundation-funded internship program, said the study has important ramifications in anionophore design, crystal engineering and other aspects of supramolecular chemistry. In fact, he said, the findings indicate that prior designs may be flawed, incomplete or even misleading. "We discovered an unexpected bonding motif that involves the transfer of charge from the anion to the arene -- in other words, a covalent bonding motif," Hay said. "This is the first theoretical characterization of what we have termed an off-center, weak charge-transfer interaction."

Anions, of which notable examples include DNA, nitrate, pertechnetate, cyanide and chromate, play indispensable roles in biological and chemical processes, but they also can contribute significantly to environmental pollution that threatens aquatic life cycles and human health.

Johnson, in collaboration with UO chemist Michael M. Haley, now is seeking to design receptors that aim to the off-center location, with a goal of developing sensors for anion detection. Because Berryman's research produced sometimes intense color changes at binding sites, such an approach could lead to developing materials that sense the presence of these toxins and remediate them.

While 0.2 nanometers seems an insignificant distance, it could mean there's a 100 percent chance that binding cannot occur, Johnson said. "We're finding that from a design standpoint, that 0.2 nanometers is a big di
'"/>

Contact: Jim Barlow
jebarlow@uoregon.edu
541-346-3481
University of Oregon
13-Dec-2006


Page: 1 2 3

Related biology news :

1. Biodesign Institute leads innovative project to prevent cancer
2. Alzheimers drug based on Purdue -- designed inhibitor begins clinical trials
3. UGR researchers design an alternative to blood test to detect drugs in the body
4. New designer lipid-like peptide with lipid nanostructures for drug delivery systems
5. The Institute of Ecosystem Studies to host an international conference on ecology and urban design
6. Pump design could give new hope to heart patients
7. UCLA scientists design masks to hide genetic mutations from cell
8. Center for Science Writings debate: Redesigning Humanity, March 21
9. Computer-designed molecule to clean up fluorocarbons?
10. Delft University of Technology designs language development toy for autistic children
11. Medieval Islamic designs reveal breakthrough in tiled pattern-making

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nano design adjustment may help find clear some water contaminants

(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: